data13F

JANX – Janux Therapeutics Inc

Held by 1 of 60 tracked investors in their latest 13F filing · 0 counted on Most owned (narrow-view filings excluded)

Investors holding1
Combined shares23,307
Combined reported value$403K

JANX chart by TradingView. Live prices are TradingView's; all other numbers on this page are from 13F filings.

Ownership

Investor% of their portfolioChangeSharesReported valuePeriod
Paul Tudor Jones narrow view 0.00 Reduced 17.0%23,307$403KQ3 2026

Activity: last 4 quarters

PeriodInvestorChangeShares afterEffect on their portfolio (pts)
Q3 2026Paul Tudor Jones narrow view Reduced 17.0%23,3070.00
Q2 2026Paul Tudor Jones narrow view Reduced 5.5%28,0700.00
Q1 2026Paul Tudor Jones narrow view Reduced 62.5%29,6890.00
Q4 2025Paul Tudor Jones narrow view Reduced 19.7%79,1580.00

Added: opened or increased

No tracked investor opened or increased this position in the last 4 quarters.

Reduced: reduced or closed

PeriodInvestorChangeShares afterEffect on their portfolio (pts)
Q3 2026Paul Tudor Jones narrow view Reduced 17.0%23,3070.00
Q2 2026Paul Tudor Jones narrow view Reduced 5.5%28,0700.00
Q1 2026Paul Tudor Jones narrow view Reduced 62.5%29,6890.00
Q4 2025Paul Tudor Jones narrow view Reduced 19.7%79,1580.00

History

1 peakQ3 2026: 1 tracked investors
Q1 2024: 1 tracked investorsQ2 2024: 1 tracked investorsQ1 2025: 1 tracked investorsQ2 2025: 1 tracked investorsQ3 2025: 1 tracked investorsQ4 2025: 1 tracked investorsQ1 2026: 1 tracked investorsQ2 2026: 1 tracked investorsQ3 2026: 1 tracked investors
20242026
Tracked investors reporting this stock, by quarter

Shares held, last 8 quarters

InvestorQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024
Paul Tudor Jones23.3K28.1K29.7K79.2K98.6K113.7K174.3K–

– = not held that quarter. n/a = no holdings report for that quarter (not filed yet, or reported under another manager).